Background: Osteoarthritis (OA) is a common disease characterized by cartilage degeneration and joint remodeling. The underlying molecular changes underpinning disease progression are incompletely understood, but can be characterized using recent advances in genomics technologies, as the relevant tissue is readily accessible at joint replacement 5 surgery. Here we investigate genes and pathways that mark OA progression, combining genome-wide DNA methylation, RNA sequencing and quantitative proteomics in isolated primary chondrocytes from matched intact and degraded articular cartilage samples across twelve patients with OA undergoing knee replacement surgery. Results: We identify 49 genes differentially regulated between intact and degraded cartilage 10 at multiple omics levels, 16 of which have not previously been implicated in OA progression.
RESULTS
In the discovery population we extracted cartilage and subsequently isolated chondrocytes from the knee joints of 12 OA patients undergoing total knee replacement surgery (see Methods). We obtained two cartilage samples from each patient, scored using the OARSI cartilage classification system [12, 13] : one sample with high OARSI grade signifying high- 5 grade degeneration (referred to as "degraded sample"), and one sample with low OARSI grade signifying healthy tissue or low-grade degeneration (referred to as "intact sample") ( Supplementary Figure 1) . We compared the degraded and intact tissue across patientmatched samples.
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Quantitative proteomics
We used isobaric labeling liquid chromatography-mass spectrometry (LC-MS) to quantify the relative abundance of 6540 proteins that mapped to unique genes. This is the most comprehensive differential proteomics study on OA samples to date. We identified 209 proteins with evidence of differential abundance ( Supplementary Table 1 ); ninety were 15 found at higher abundance in the degraded samples, and 119 were found at lower abundance. For two representative patients we also used an orthogonal label-free approach that confirmed the protein quantification data ( Supplementary Figure 2) . For three of the differentially abundant proteins (ANPEP, AQP1 and TGFBI), we validated the higher levels in degraded cartilage by Western blotting (Supplementary Figure 3) . All three were also 20 detected as significant in the RNA sequencing data (see below).
RNA sequencing
We sequenced total RNA from all samples and identified 349 genes differentially expressed at a 5% false discovery rate (FDR). Of these, 296 and 53 genes demonstrated higher 25 transcription levels in the degraded and intact samples, respectively (Supplementary Table  2 ). One of the most strongly down-regulated genes in chondrocytes isolated from damaged sites was CHRDL2, the presence of which was further confirmed by immunohistochemistry (IHC; Supplementary Figure 4 ). This gene was also found at lower abundance in the proteomics data.
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DNA methylation
We used the Illumina 450k methylation array to assay ~480,000 CpG sites across the genome.
We first performed a probe level analysis and identified 9,896 differentially methylated probes (DMPs) at 5% FDR ( Supplementary Table 3 ). We also identified 271 differentially methylated regions (DMRs), composed of multiple differentially methylated CpG sites (see 10 Methods), associated with 296 unique overlapping genes ( Supplementary Table 4 ).
Integrative analyses: proteomics and RNA sequencing
Among the 209 proteins with evidence of differential abundance in the proteomics data, 31
were also differentially expressed at the RNA level (hypergeometric p=5.3x10 -7 , Figure 1b ). 15 Twenty-six of these 31 genes showed concordant directions of effect between degraded and intact samples (binomial p=0.0002), while the direction differed for five (COL4A2, CXCL12, FGF10, HTRA3 and WNT5B). In all five cases the gene was found to be over-expressed at the RNA level and less abundant at the protein level in the degraded tissue. Based on the Human Protein Atlas [14] , all five proteins encoded by these genes are annotated as predicted 20 secreted proteins. In agreement with this, several collagens are more abundantly released into the culture media from diseased tissue than from healthy tissue [15] .
We computed the global correlation in all samples irrespective of tissue status, comparing the RNA fragments per kilobase of transcript per million fragments mapped (FPKM) [16] to 25 normalized peptide spectral counts ( Supplementary Figure 5a) and found a significant positive correlation (Spearman's rho=0.29, p<2.2x10 -16 ) between RNA expression levels and protein abundance. To establish if there were also concordant differences in RNA and protein abundance between intact and degraded tissue, we computed the correlations between RNA and protein changes in degraded compared to intact samples (Figure 2a ), and identified a significant positive correlation (Pearson's r=0.17, ). The magnitude of 5 correlation became substantially stronger when we only considered the 31 genes that were expressed differentially in both datasets (Pearson's r=0. 43, p=0 .01).
Integrative analyses: methylation and RNA sequencing
Sixteen of the genes with an associated DMR were also differentially transcribed (Figure 1b ).
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For the direct comparison of methylation and gene expression in the following, we used the aggregate methylation status of promoter region CpG probes with transcription levels in all samples irrespective of intact/degraded status (see Methods, Supplementary Table 5 ). We found the expected negative correlation between promoter region methylation and gene expression (Spearman's rho=-0.43, p<2.2x10 -16 , Supplementary Figure 5b ). Based on the 15 comparison of intact to degraded cartilage, the log-fold-changes in RNA expression and the differences in mean promoter region methylation values demonstrated a small but highly significant correlation (Pearson's r=-0.08, p<2.2x10 -16 , Figure 2b ). Again, the correlation became substantially higher when we considered the 39 genes with significant differences at both the promoter methylome and transciptome levels (Pearson's r=-0.48, p=0.002).
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Integrative analyses: methylation, RNA sequencing, and proteomics
We identified 49 genes with evidence of differential regulation from at least two of the three -omics analyses (using the DMR methylation data; Supplementary Table 6 ), and three genes with consistent significant evidence for involvement in OA progression across all three 25 levels: AQP1, COL1A1 and CLEC3B (Figure 1b ). All three genes were up-regulated in degraded tissue in both the RNA-seq and proteomics analyses (Figure 2a ). AQP1 and COL1A1 showed a consistent decrease in methylation of all CpG probes in their associated DMRs, commensurate with an increase in transcription, while the DMR associated with CLEC3B showed evidence of increased methylation. Using IHC we independently confirmed the presence of AQP1, COL1A1 and CLEC3B in articular cartilage chondrocytes (Supplementary 5 Figure 4 ). We also replicated the direction of gene expression change for all three genes in independent data (see below and Supplementary Table 7) .
Of the 49 genes with evidence of differential regulation on at least two molecular levels, 33 add substantive evidence to genes previously reported and 16 genes (33%) have not previously been implicated in OA ( Supplementary Table 6 ).
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Replication of gene expression changes
We assayed gene expression in degraded and intact cartilage samples from two independent cohorts: a set of 17 patients with knee OA and a set of 9 patients with hip OA, using the same approach as for the discovery data (see Methods). After quality control, we retained 15 14,762 genes common to the discovery and both replication datasets, including 332 of 349 genes with FDR≤5% in the discovery data. We found excellent concordance in the direction of change for the genes with FDR≤5% in the discovery data: 93.4% of genes showed the same direction of effect in the knee replication data and 91.0% of genes showed the same direction of effect in the hip replication data (Figure 3a-b; both binomial p<10 -15 ). Of the 20 genes with concordant effect between the discovery and replication data, 65.5% reached nominal statistical significance in the knee replication data and 47% in the hip replication data ( Supplementary Table 8 ; both binomial p<10 -15 ).
Moreover, we found good correlation for the estimates of the log-fold-changes across all replication data and r=0.51 for hip replication data (both p<10 -15 ). These correlations are higher for the 332 genes with FDR≤5% in the discovery gene expression data (r=0.73 for knee, r=0.66 for hip replication data, both p<10 -15 ). This shows that the gene expression changes identified in this study are robust and largely joint-independent. 5 We specifically considered the 49 genes with evidence from at least two -omics levels. Of these, 47 had gene expression data in the discovery and both replication datasets; 36 genes had nominally significant differential gene expression in the same direction in the knee replication data, and 26 genes in the hip replication data ( Supplementary Table 7 ). This included ANPEP, for which we have used Western blotting to confirm protein changes 10 (Supplementary Figure 3) , and CHRDL2, for which we used immunohistochemistry to confirm presence of the protein (Supplementary Figure 4) . Notably, the direction of change replicates in at least one of the knee and hip replication datasets at nominal significance for 13 of the 16 genes that have not previously been associated with OA ( Supplementary Table   7 ). 15 We also pursued replication in an independent published microarray gene expression dataset of degraded and intact cartilage from the RAAK study, including 22 individuals with hip OA and 11 individuals with knee OA [17] . Of the 349 genes with FDR≤5% in the discovery data, 154 genes had expression measurements in the RAAK knee and hip replication 20 datasets. We found highly significant agreement between the discovery and RAAK data: 83.8% of the genes showed the same direction of effect in the knee RAAK data (binomial one-sided p<10 -15 ) and 69.5% of genes showed the same direction of effect in the hip RAAK data (binomial one-sided p<10 -6 ). Furthermore, despite the difference in genomics technology (RNA-seq in discovery, microarray in RAAK), we found good concordance for the 25 estimates of the log-fold-changes between the knee discovery and the RAAK replication data: r=0.43 for knee (p=3.6x10 -8 ) and r=0.24 for hip replication data (p=0.003).
Replication of methylation changes
To replicate the methylation results, we assayed DNA methylation in degraded and intact 5 cartilage samples from two independent datasets: a set of 17 patients with knee OA and a set of 8 patients with hip OA, using the same approach as for the discovery data (see Methods). After quality control, we retained 416,437 probes common to the discovery and both replication data sets, including 9,723 of 9,867 differentially methylated probes (DMPs) with FDR≤5% in the knee discovery data. We found excellent concordance in the direction of 10 change for the DMPs: 96.9% of probes showed the same direction of effect in the knee replication data and 95.2% probes showed the same direction of effect in the hip replication data (Figure 3c-d; both binomial one-sided p<10 -15 ).
Furthermore, we found good correlation for the estimates of the fold-changes across all 15 416,437 probes between the knee discovery and the replication data: r=0.69 for knee replication data and r=0.56 for hip replication data (both p<10 -15 ). The correlation is even higher for the DMPs: r=0.91 for knee, r=0.85 for hip replication data (both p<10 -15 ).
Similarly to the gene expression data, this shows that the methylation changes estimated in this study are robust and largely joint-independent.
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In summary, our combined epigenetic, transcriptomic and proteomic analysis has uncovered a substantial number of genes associated with OA progression, some of which have known connections to cartilage or bone-related processes, and others with no links reported to date, bringing new potential insights into the molecular mechanisms of OA pathogenesis.
The replication data confirm the high quality of our discovery experiment and further support a large number of the novel genes with a suggested role in OA progression.
Gene set analyses
We performed a gene set enrichment analysis on the genes with significant evidence for 5 differential expression, methylation and/or protein abundance from each separate -omics analysis and found that several common biological processes are highlighted at multiple levels (Supplementary Tables 9-10). We additionally identified pathways jointly affected by genes identified at multiple molecular levels (Figure 4 , Supplementary Figure 6 , Supplementary Tables 9-10).
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A strong theme in the highlighted pathways is cartilage matrix regulation and degeneration, confirming the fact that increased ECM turnover is a crucial component in OA pathogenesis.
Pathways including extracellular matrix organization and collagen formation were also implicated by genes identified by all three -omics analyses ( Figure 4 ). Results from the three 15 analyses converge on shared mechanisms, supporting the importance of taking an integrated perspective. The GO term analysis also uncovered consistent evidence from all three -omics assays for genes annotated for extracellular matrix disassembly and collagen catabolic process. In these pathways we also find suggestive evidence of a link to genetic OA risk loci (see Supplementary Methods and Results, Supplementary Table 11 ). These signals 20 would not necessarily have been identified directly from GWAS data, highlighting the importance of synthesizing information from multiple molecular levels to obtain a more powerful integrated view.
Positive regulation of ERK1/2 cascade, heparin-binding and platelet activation were also 25 enriched at multiple molecular levels and are interconnected through common genes.
Several studies have linked the extracellular signal-regulated kinase (ERK) cascade to OA [5, 18-21]. Heparin-binding growth factors have also been shown to be involved in OA [22-25], some in particular through activation of the ERK signaling pathway. Injection of platelet-rich plasma in OA knees leads to significant clinical improvement [26, 27] and there is evidence to suggest that this effect is mediated via the ERK cascade [28] . Our findings provide strong 5 evidence supporting a role for this pathway in OA pathogenesis.
We also found enrichment of genes involved in the regulation of angiogenesis at multiple levels. The growth of blood vessels and nerves are closely linked processes that share regulatory mechanisms, including the ERK cascade and heparin-binding proteins mentioned 10 above [29] . Accordingly, NCAM signaling for neurite outgrowth and PDGF signaling that play a significant role in blood vessel and nervous system formation were highlighted by the pathway analysis. We found significant enrichment in plasma proteins for both the RNA-seq (hypergeometric p=6.9x10 -11 ) and the proteomics experiments (p=1.8x10 -5 ). This supports a role for angiogenesis and nerve growth in OA progression [29, 30] . Indeed, histological 15 examination of the samples we investigated showed greater blood vessel ingrowth in tissues with more advanced OA ( Supplementary Figure 1) . Results from the three molecular analyses converge on shared biological mechanisms that are relevant to the pathogenesis of OA. These data should be useful in pinpointing candidate targets to help improve therapeutic intervention.
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In silico screen for drug targets
To identify existing drugs that could be applied to OA, we searched Drugbank [31] Supplementary   Table 12 ). For the corresponding nine genes, eight have RNA-seq data, and the direction of change replicates for seven genes in the knee and six genes in the hip RNA-seq replication data at nominal significance ( Supplementary Tables 8,12 ). Consequently, this work could 5 help prioritize the repurposing of existing drugs for the treatment of OA.
DISCUSSION
Previous studies of osteoarthritis have investigated methylation [32, 33] , transcription [17, 34, 35] , or protein expression [36, 37] in OA tissue separately, and others have combined up to two of these -omics assays [38, 39] , some with the addition of genetic data [40] . By contrast, this study provides the first integrated, systematic and hypothesis-free analysis of 5 the biological changes involved in human cartilage OA progression using genome-wide data at three molecular levels. Using this multi-level functional genomics approach, we have provided a first integrated view of the molecular alterations within chondrocytes that accompany cartilage degeneration leading to debilitating end-stage joint disease. All data arising from the experiments described here are freely available to the wider scientific 10 community, from the raw data to the analysis results for each -omics level.
We show that the direction of effect for over 90% of gene expression and CpG methylation changes replicate in independent knee or hip OA data. We also replicate the majority of gene expression changes using independent knee and hip OA data from a microarray 15 experiment. This supports the quality of our data and suggests that there are largely shared molecular changes in knee and hip OA progression, within the power constraints of our study.
We have focused on improving our understanding of the molecular processes that underpin 20 disease progression and have used matched intact and degraded cartilage samples from knee OA joints. Our data highlight 49 genes with evidence of differential regulation at multiple molecular levels, identifying several novel genes, including MAP1A and PXDN, and providing robust cross-cutting evidence for genes previously implicated in OA, including AQP1, COL1A1, and CLEC3B. AQP1 encodes aquaporin-1, a member of a family of proteins that facilitate water transport across biological membranes. Chondrocyte swelling and increased cartilage hydration has been suggested as an important mechanism in OA [41]. Accordingly, AQP1 has been observed to be over-expressed in a rat model of knee OA [42] , and in knee OA in humans [43] . 5 CLEC3B (also known as TNA) encodes the protein tetranectin, which binds human tissue plasminogen activator (tPA) [44] . Previous studies have identified CLEC3B as up-regulated in human OA [34, 45] , mediating extracellular matrix destruction in cartilage and bone [46] , and a candidate gene association study found evidence of association of a coding variant 10 (rs13963, Gly106Ser) in CLEC3B with OA [47] (although this association has not been replicated in subsequent studies [48] ).
COL1A1 is one of several collagen proteins, which were differentially abundant at both the RNA-seq and proteomics levels (including COL1A2, COL3A1, COL4A2, COL5A1, 15 Supplementary Table 6 ). Collagens are the main structural components of cartilage and several studies have highlighted the importance of collagen dysregulation in OA [6, 49] . A recent study also identified up-regulation of COL1A1 and COL5A1 in synovium from humans with end-stage OA, in the synovium of mice with induced OA and in human fibroblasts stimulated with TGF-β [50] .
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MAP1A and MAP1B, two novel genes with convergent evidence confirmed by replication, encode microtubule-associated proteins, both of which were up-regulated significantly at both the RNA and protein levels (Figure 2a ). These proteins are expressed mostly in the brain and are involved in regulation of the neural cytoskeleton [51] . Cytoskeletal regulation is thought to be an important process in OA [52] and accordingly, recent studies have implicated these proteins in bone formation [53] .
The PXDN gene was up-regulated at the RNA level, confirmed by replication, and associated with 2 hypo-methylated DMRs. PXDN encodes peroxidasin, which is secreted into the 5 extracellular matrix and catalyses collagen IV cross-linking [54] . The other replicated genes not previously implicated in OA ( Supplementary Table 6 ) have relatively little characterization.
Among the genes we identify that have been previously implicated in OA, ANPEP 10 (aminopeptidase E) is a broad specificity aminopeptidase that has previously been detected in the synovial fluid of OA patients [55] and therefore has potential as a novel OA biomarker.
CHRDL2 is a bone morphogenetic protein (BMP) inhibitor that has previously been reported to be lost from chondrocytes of the superficial zone and shifted to the middle zone in OA cartilage in a targeted study [56] . WNT5B, a ligand for frizzled receptors in the WNT signaling 15 pathway, has previously been reported to be differentially transcribed in osteoarthritic bone, consistent with current understanding that OA is a disease involving both cartilage and bone
On the level of gene sets, we identify extracellular matrix organization, collagen catabolism 20 and angiogenesis as biological pathways that are clearly implicated in disease progression.
Intervention to prevent disease progression in OA as well as targeted prevention in high-risk disease-free individuals will be important in reducing the future societal burden of OA [58] .
A clearer understanding of the factors that modulate OA disease progression is thus critical 25 to the development of novel prognostic markers and biological disease-modifying agents, analogous to those emerging or successfully applied in inflammatory arthritis [59] [60] [61] .
Follow-up mechanistic studies will be required before causal relationships between the identified pathways and OA progression can be established.
In the chondrocyte, we found little evidence of differential inflammatory pathway activity 5 between the intact and degraded samples [62, 63] . This is not surprising, as all of the patients whose tissues were studied here had a diagnosis of OA and clinically advanced disease in at least 1 location within the joint. Inflammatory mediators are soluble factors present throughout the joint, to which both the healthy and the diseased chondrocyte populations are potentially exposed, and for which the regulatory molecules may differ to 10 those prioritized by the tissues studied here.
Based on our discovery data from 12 individuals, we estimate that ~10% of the "true" differentially expressed genes are statistically significant in this study and ~95% of significantly different genes are true positives (Supplementary Figure 7) . The high true 15 positive rate is also confirmed by the replication data for gene expression and methylation.
Larger sample sizes will be required for a more powerful characterization of the molecular changes occurring with disease progression. The integrative functional genomics approach illustrated here offers an opportunity to identify molecular signatures in disease-relevant 20 tissues, thereby gaining insights into disease mechanism, identifying potential biomarkers, and discovering druggable targets for intervention. A key future challenge will be the development of powerful statistical approaches for the integration of high-dimensional molecular traits in the context of complex diseases.
METHODS
Patient consent & study approval
All subjects provided written, informed consent prior to participation in the study. Tissue 
Histological examination
Four micron sections of paraffin-embedded cartilage tissue were mounted onto positively charged slides and histologically stained using Haematoxylin and Eosin, Alcian blue, Masson trichrome (details see Supplementary Methods). Cartilage tissue was graded using the thickness (0-4) based on the OARSI scoring system [12, 13] . The total scores were used to determine the overall grade of the cartilage as healthy/low-grade degenerate, referred to as "intact" (median: 4.5; IOR: 3-5.5; n=12), or high-grade degenerate, referred to as "degraded" (median: 14; IOR: 11.75-18; n=12). The ten most abundant multiply charged precursors within 380 -1500 m/z were selected with FT mass resolution of 30,000 and isolated for HCD fragmentation with isolation width 1.2 Th. Tandem mass spectra were acquired with FT resolution of 7,500 and targeted 25 precursors were dynamically excluded for further isolation and activation for 40 seconds with 10 ppm mass tolerance. Samples from one individual were excluded during quality control.
Database Search and Protein Quantification
The acquired mass spectra were submitted to SequestHT search engine implemented on the 
Differential abundance
To identify those proteins with evidence of differential expression, we shortlisted proteins with absolute median abundance ratios between degraded and intact samples ≥0.75, where 20 the median abundance ratio was greater than the standard deviation in all samples with data, and with evidence from at least 5 patients. This analysis identified 209 proteins (Supplementary Table 1 ).
Western blotting
Sample pairs were adjusted to the same protein concentration. Primary antibodies used were as follows: ANPEP, ab108382; AQP1, ab168387; COL1A, ab14918; TGFB1, ab89062; WNT5B, ab124818 (Abcam); GAPDH, sc-25778 (Santa Cruz Biotechnologies). Intensity values were normalized to GAPDH loading control before ratio calculation. Further details are in the Supplementary Methods. Figure 2) . 15 
RNA-seq
Detailed protocols for all individual steps are included in the Supplementary Methods.
RNA sequencing
The steps for mRNA purification, cDNA library creation, and litigation to Illumina Paired-end 
Read alignment
The resulting reads that passed QC were realigned to the GRCh37 assembly of the human 5 genome using a splice-aware aligner, bowtie version 2.2.3 [64], and using a reference transcriptome from Ensembl release 75 [65] , using the -library-type option fr-firststrand to bowtie. We limited the alignments to uniquely mapping reads. We then counted the number of reads aligning to each gene in the reference transcriptome using htseq-count from the HTSeq package [66] separately for each sample to produce a read count matrix counting the 10 number of reads mapping to each gene in the transcriptome for each sample. To quantify absolute transcript abundance we computed the fragments per kilobase of transcript per million fragments mapped (FPKM) [16] for each gene using the total read counts from this matrix, and the exonic length of each gene calculated from gene models from Ensembl release 75. We obtained a mean of 49.3 million uniquely mapping reads from each sample 15 (range: 39.2-71.4 million) with a mean of 84% of reads mapping to genes (range: 67.9-90.6%) which were used for the differential expression analysis.
Differential expression analysis
We used edgeR version 3.0 [67] to identify differentially expressed genes from the read 20 count matrix. We restricted the analysis to 15,418 genes with >1 counts per million in at least 3 samples (similar to the protocol described by [68]). We followed the processing steps listed in the manual, using a generalized linear model with tissue status (degraded or intact) and individual ID as covariates. 349 genes were differentially expressed between the degraded and intact samples at 5% FDR (296 up-, 54 down-regulated in degraded tissue).
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The genes differentially expressed at 5% FDR had somewhat higher exonic length than the remaining genes (Wilcox-test p=0.00013; 4804 vs 4153 bases), hence we adjusted for gene length in the randomizations for gene set analyses (see Supplementary Methods) .
Methylation
We used the Illumina 450k BeadChip to assay methylation, with sample preparation 5 (including Bisulfite Conversion, pre-and post-amplification) described in detail in the Supplementary Methods.
Illumina 450k BeadChip assay
BeadChips were scanned on five Illumina iScans, four of which are paired with two Illumina Autloader 2.Xs. The iScan software produced intensity files for each channel (.idat files).
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Probe-level analysis
The intensity files for each sample were processed using the ChAMP package [69] . Probes mapping to chromosomes X & Y, and those with a detection p-value >0.01 (n=3,064) were excluded. The beta values for each probe were quantile-normalized, accounting for the 15 design of the array, using the 'dasen' method from the wateRmelon package [70] . We also excluded any probes with a common SNP (minor allele frequency >5%) within 2 base pairs of the CpG site, and those predicted to map to multiple locations in the genome [71] (n=45,218), leaving a total of 425,694 probes for the probe-level differential methylation analysis. We annotated all probes with genomic position, gene and genic location 20 information from the ChAMP package.
To identify probes with evidence of differential methylation we used the CpGassoc package [72] to fit a linear model at each probe, with tissue status and individual ID as covariates.
This analysis yielded 9,867 differentially methylated probes (DMP) between degraded and 25 intact samples at 5% FDR.
Region-level analysis
To identify differentially methylated regions, we used custom software (available upon request) to identify regions containing at least 3 DMPs and no more than 3 non-significant probes with no more than 1kb between each constituent probe, following previous analyses 
Promoter-level analysis
We assigned probes in the promoter region of each gene using the probe annotations from the ChAMP package, and assigned to each gene any probe with the annotation "TSS1500", "TSS200", "5'UTR" and "1stExon" in order to capture probes in likely promoter regions. We then computed the mean normalized beta value of assigned probes for all genes with at 15 least 5 associated probes for each sample separately, to produce a single methylation value for each gene in each sample. We used a paired t-test to identify genes with differential promoter-region methylation between degraded and intact samples, and a 5% FDR cutoff to call a gene's promoter region as differentially methylated. Note that the paired t-test assumes an equivalent model to the linear model used for the probe-level analysis.
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Immunohistochemistry
To identify whether native chondrocytes demonstrated expression of the key factors immunohistochemistry was deployed. The detailed protocol is included in the Supplementary Methods.
Protein atlas annotation
We downloaded annotations from Human Protein Atlas version 13, and annotated each protein-coding gene from the 3 experiments with the following terms taken from the annotation file: "Predicted secreted protein", "Predicted membrane protein", "Plasma protein". The secreted and membrane protein predictions are based on a consensus call 5 from multiple computational prediction algorithms, and the plasma protein annotations are taken from the Plasma Protein Database, as detailed in [14] .
Identification of previously reported OA genes
In order to identify whether some of the genes we highlight have previously been reported 10 as associated with OA, we searched PubMed on 2 September 2016. We used an "advanced" search of the form "(osteoarthritis) AND (<gene_name>)" where <gene_name> was set to each HGNC gene symbol and we report the number of citations returned for each search. All sample processing steps (extraction of chondrocytes, extraction of DNA) were carried out as for the knee OA discovery samples.
Replication of gene expression changes using RNA-seq data and replication of methylation
Hip samples
Tissue samples were collected under national Research Ethics approval reference 11/EE/0011, Cambridge Biomedical Research Centre Human Research Tissue Bank, Cambridge University Hospitals, UK. All samples were collected from patients undergoing total hip replacement for primary osteoarthritis. The patients, who provided written consent 5 before participation, comprised 6 women and 3 men, mean age 61 years (range 44-84).
Patients with diagnosis other than osteoarthritis were excluded from the study. All sample processing steps (extraction of chondrocytes, extraction of DNA) were carried out as for the knee OA discovery samples, except that the cartilage was digested overnight in 6mg/ml collagenase A (Roche) in medium containing 10% serum to release the cells.
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Replication analysis for gene expression changes: RNA-seq data
We applied the same procedure to the knee and hip replication data as to the discovery data.
We considered 14762 genes that passed QC in the knee discovery, knee replication, and hip replication data; this included 332 of 349 genes with FDR<=5% in the knee discovery data.
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Replication analysis for methylation changes
We used the Illumina 450k BeadChip to assay methylation for all knee and hip replication samples, using the same procedure as for the knee discovery data. The knee and hip methylation data were processed using the same QC procedure as for the knee discovery 20 samples, including the same QC thresholds. We excluded one degraded hip cartilage sample as an outlier in probe failure rate (over six times the proportion of the next highest sample), and also excluded the paired intact cartilage sample. After QC, 417077 probes remained.
We considered 416437 probes with methylation values in the knee discovery, knee replication, and hip replication data; this included 9723 of 9867 probes with FDR<=5% in the 25 knee discovery data ("DMPs").
Replication of gene expression changes: microarray data
OA-dependent changes in expression of genes with differential expression in the discovery data were assessed with the help of an available dataset from the ongoing Research Arthritis and Articular Cartilage (RAAK) study, consisting in gene expression profiles of OA affected 5 cartilage and macroscopically preserved cartilage from 33 patients undergoing total joint replacement surgery (22 with hip OA, 11 with knee OA). Sample collection and determination of gene expression levels have been described in detail previously [17] . In short, cartilage was collected separately for the OA affected and the unaffected regions of the weight baring part of the joint, snap frozen in liquid nitrogen and stored at -80°C prior to 10 RNA extraction. Gene expression was determined with the Illumina HumanHT-12 v3 microarrays. After removal of probes that were not optimally measured (detection p-value >0.05 in more than 50% of the samples) a paired t-test was performed on all sample pairs while adjusting for chip (to adjust for possible batch effects).
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Gene set analyses
Individual datasets
We aimed to test whether particular biological gene sets were enriched among the significant genes from each of the RNA-seq, methylation, and proteomics datasets. To this end, we downloaded KEGG [74] and Reactome [75] gene annotations from MSigDB (version 20 4) [76] . We also downloaded Gene Ontology (GO) biological process and molecular function gene annotations from QuickGO [77] on 4 February 2015. For GO, we only considered annotations with evidence codes IMP, IPI, IDA, IEP, and TAS. Genes annotated to the same term were treated as a "pathway". KEGG/Reactome and GO annotations were analysed separately and only pathways with 20 to 200 genes were considered (555 for and only considering genes with annotations from a particular resource, as described in the Supplementary Methods. Multiple-testing was accounted for by using a 5% FDR (separately for KEGG/Reactome and GO, and for RNA-seq, methylation, and protein expression data).
Empirical p-values for the enrichments were obtained from randomizations accounting for 5 overlap of significant genes among the RNA-seq, methylation, and protein expression datasets (see Supplementary Methods) .
Integrative gene set analyses
We aimed to integrate the gene sets analyses for the RNA-seq, methylation, and protein 10 expression datasets. For each gene set, we asked whether the association across the three datasets (calculated as geometric mean of the p-values) was higher than expected by chance.
To this end, we obtained 1-sided empirical p-values from 100,000 sets of "random RNA-seq genes, random methylation genes, and random protein expression genes". The "random" sets were chosen to conservatively match the overlap observed among the significant genes, 15 and to account for gene length as described in the Supplementary Methods. We confirmed that the number of randomizations was sufficient (see Supplementary Methods). We performed the randomization separately for KEGG/Reactome and for GO, as we only considered genes with at least one annotation in the resource.
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Analyses using the arcOGEN genetic data are described in the Supplementary Methods and in the Supplementary Results.
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Availability of data and material
Figure 4: Significant gene set enrichments in the integrative -omics analysis.
a, b) Enrichments from KEGG/Reactome (a) and Gene Ontology (b). The circos plots show enriched gene sets, with genes differentially regulated in at least one of the methylation, RNA-seq, or proteomics experiments. Lines connect genes that occur in several gene sets. The three outside circles show boxes for genes with significantly higher (black) or lower (red)
